Reported by the FDA: The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot. Accelerating clinical trial timelines and eliminating regulatory hurdles to maintain American leadership in global medical innovation is a core priority for the Trump Administration. Driven by the President's directive, the pilot seeks to accelerate the time it takes from identifying a drug to initiating a first-in-human clinical trial by partnering drug companies with qualified research institutions (QRI) that have scientific expertise to support efficient development of IND applications. The FDA will accept applications to participate in the pilot until October 30, 2026.

Currently, first-in-human clinical trials may take up to two years to complete in the United States. The same types of trials are completed much faster in China and Australia, threatening America's leadership in scientific innovation. As a key component of the Trump Administration's healthcare modernization efforts and as part of the U.S. Department of Health and Human Services' Operation TrialBlazer, the FDA has committed to proactively addressing these clinical development challenges through dedicated initiatives such as the Expedited IND Pilot.

"The pilot not only pairs industry innovators with top research institutions to accelerate high-quality data being submitted to the FDA, it also tests if the partnership can accelerate what happens after the FDA allows a clinical trial to proceed," said Acting FDA Commissioner Kyle Diamantas, J.D. "Under the Trump Administration, boosting domestic innovation and ensuring American patients have first access to groundbreaking treatments is a top priority. The FDA will continue implementing Operation TrialBlazer to modernize regulatory processes to keep our country ahead of global competitors without compromising patient safety."

More> 

You may be interested in our 2nd Maternal & Child Health Symposium on Sept. 28th, 2026. Full Day- Eight Sessions - 12 Speakers. For more details and to register> 

###